GlaxoSmithKline Bangladesh

Company Overview

GlaxoSmithKline (GSK) is a science-led global healthcare company that researches and develops a broad range of innovative medicines, vaccines and consumer healthcare products. Our products are used by millions of people around the world, helping them to do more, feel better and live longer. With Headquarters in UK, GSK has a wide geographical reach which includes 115 countries, manufacturing network in 87 sites and more than 100,000 people working globally. We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. As a research based company we believe in creating innovative new products and making these accessible to as many people who need them.

As a part of the centuries old company, GSK Bangladesh, a subsidiary of GSK plc, started its operation in Bangladesh (the then East Pakistan) in 1949. GSK Bangladesh’s activities include secondary manufacturing of pharmaceutical products and marketing of vaccines, pharmaceutical healthcare products, nutrition and oral healthcare products. Our activities in all three business areas are strictly guided by “GSK values” which include showing respect for people, being patient/customer focused and commitment to transparency and demonstration of highest integrity in our conduct. Embedded with these values and backed by leading edge technology, around 1,000 people are working across the country with the global mission to improve the quality of human life by ensuring quality healthcare products. 

In the more than six decades since its inception in Bangladesh, the Company has evolved from being an importer to manufacturer by establishing its own manufacturing unit in Chittagong in 1967. Following the mergers and acquisition it also underwent identity evolution from Glaxo to Glaxo Wellcome to finally GlaxoSmithKline Bangladesh Limited in 2002.

GSK Bangladesh’s Vaccine unit leads the market not only in terms of volume but also in terms of providing a whole range of disease prevention for both infants and adults. In March 2015 GSK ,  pneumococcal vaccine  was introduced  in the Bangladesh  Government’s Expanded Program for Immunization (EPI).

Till today, GSK Bangladesh continues to rank amongst the leaders in the respiratory and anti-infective therapeutic areas and we proudly hold on to our  leadership position in dermatology.  The acquisition of Stiefel Laboratories, the world’s largest independent dermatology company have further strengthened our position in the derma world and  have further created our footprint in to the aesthetic skin health care arena.

The Consumer Healthcare unit leads the Health Food Drink (HFD) category in Bangladesh and is now set on its journey in creating a strong footprint in the Oral Health Care and Vitamins & Mineral Supplement (VMS) category . In each of these categories, GSK has flagship brands like HorlicksTM, SensodyneTM, GlaxoseTM etc.

GSK has made a global commitment to re-invest 20% of the profits it makes in developing countries to address issues around providing healthcare services to the underserved communities. In line with that, we have been investing more than 1 million GBP per year since 2010 in Bangladesh in a number of projects in partnerships with CARE, icddr,b and Friendship.

GSK is committed to developing new and effective healthcare solutions. The values on which the group was founded have always inspired growth and will continue to do so in times to come.